MetaCap

Oruka Therapeutics (ORKA) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oruka Therapeutics (ORKA) has outperformed Alpha Teknova (TKNO) over the past year, gaining 227.1% versus a gain of 77.4%. Over five years, ORKA leads with a +205.9% price change compared with -63.6% for TKNO. Oruka Therapeutics is the larger company by market cap ($6.50 billion vs $480.0 million), about 13.5 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ORKA+227.11%TKNO+77.44%
+303%+116%-71%
Nov 21, 20251 yearNov 20, 2026
ORKA+238.31%TKNO-69.50%
+311%+98%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ORKA versus TKNO key metrics
MetricORKATKNO
Share price$95.81$7.63
Market cap$6.50B$479.95M
1-day change-1.80%-2.30%
YTD return+216.10%+100.79%
1-year return+227.11%+77.44%
5-year return+205.91%-63.63%
EPS (TTM)$-2.12$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$40.52M
Revenue growth (YoY)—+7.35%
Net income (latest FY)$-105.43M$-17.26M
Gross margin—33.17%
Operating margin—-41.90%
Net margin—-42.59%
52-week high$115.52$9.48
52-week low$25.23$1.91
Distance from 52-week high-17.06%-19.51%
Analyst consensusstrong_buynone
Avg. price target upside+63.00%+28.83%
Average volume965.27K437.31K
Shares outstanding67.82M62.90M
Employees68158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Oruka Therapeutics is about 13.5 times larger than Alpha Teknova by market value ($6.50B vs $479.95M).
  • ORKA has outperformed TKNO by 149.7 percentage points over the past year.

About Oruka Therapeutics

ORKA stock →

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

ORKA vs TKNO FAQ

Which is bigger, Oruka Therapeutics or Alpha Teknova?

Oruka Therapeutics (ORKA) is larger, with a market capitalization of $6.50B compared with $479.95M for Alpha Teknova (TKNO).

Which stock has performed better over the past year, ORKA or TKNO?

ORKA returned +227.11% over the past 12 months, compared with +77.44% for TKNO (price return, excluding dividends). Past performance does not predict future results.

Are Oruka Therapeutics and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons